Nuvation Bio presents updated long-term Phase 2 J201 data for safusidenib in Grade 2 IDH1-mutant glioma at SNO Annual Meeting

Nuvation Bio presented updated long-term results from its Phase 2 J201 study of safusidenib, a selective mutant IDH1 inhibitor, in patients with Grade 2 IDH1-mutant glioma who had not previously received chemotherapy or radiotherapy, at the 31st SNO Annual Meeting in Philadelphia.

Detected & updated continuously · Source: Nebula

Story subjects

Track sentiment and mindshare across stocks and crypto in Nebula.

Open Nebula